Bioglutide (NA-931): Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข3 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Storage conditions for Bioglutide have not been publicly disclosed in detail. Clinical trial supplies are managed according to sponsor protocols. As a small molecule oral capsule, standard pharmaceutical storage conditions (room temperature, protected from moisture and light) are expected.
Protocol Quick-Reference
Chronic weight management in adults with obesity
Dosing
Amount
Up to 150 mg
Frequency
Once daily
Duration
13 weeks (Phase 2 trial)
Administration
Route
OralTiming
Take one capsule once daily by mouth. No fasting or food restrictions required. Blood levels consistent regardless of fasting state or high-fat meal.
Cycle
Duration
Ongoing (long-term use expected)
Repeatable
Yes
โ๏ธ Suggested Bloodwork (4 tests)
CMP (Comprehensive Metabolic Panel)
When: Baseline
Why: Baseline liver and kidney function
HbA1c
When: Baseline
Why: Baseline glycemic status
Lipid panel
When: Baseline
Why: Baseline cardiovascular risk assessment
Body composition assessment
When: Baseline
Why: Track muscle mass preservation during treatment
๐ก Key Considerations
- โInvestigational drug: not FDA-approved for any indication
- โLimited clinical data: Phase 1 (n=74) and Phase 2 (n=125) trials with short durations
- โNo peer-reviewed publications of Phase 2 data: conference abstracts only as of early 2026
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Phase 1 Dose Escalation Study (NCT06615700) | Multiple ascending doses up to 150 mg daily in overweight/obese adults over 28 days. Doses of 60 mg and above showed sustained weight loss effects. | Once daily oral capsule | 28 days | Phase 1 study in 74 otherwise healthy overweight/obese adults. Dose-dependent weight loss up to 6.4% at Day 28. Weight loss maintained or improved at Day 35 (7 days post-last dose). |
| Phase 2 Weight Loss Trial (NCT06564753) | Ascending doses up to 150 mg daily in adults with obesity or overweight with comorbidities over 13 weeks. The 150 mg daily dose achieved maximum efficacy. | Once daily oral capsule | 13 weeks | Phase 2 study in 125 adults. Maximum mean weight loss of 13.8% at 150 mg daily. 72% of treated subjects achieved at least 12% weight loss. No fasting or food restrictions required. |
| Combination Therapy with Tirzepatide (NCT06732245) | NA-931 150 mg daily oral capsule combined with tirzepatide subcutaneous injection in adults with obesity or overweight. Designed to evaluate synergistic effects. | NA-931 once daily oral; tirzepatide once weekly subcutaneous | Under investigation | Phase 2 study enrolling 224 participants. Designed to assess whether combination produces synergistic weight loss while reducing GI adverse events and preserving muscle mass. Preclinical studies showed synergistic effects on weight, glucose, and lipids. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
No reconstitution required. Bioglutide (NA-931) is supplied as an oral capsule that is taken by mouth. Unlike injectable GLP-1 receptor agonists, no mixing, dilution, or injection preparation is necessary.
๐งStorage Requirements
Storage conditions for Bioglutide have not been publicly disclosed in detail. Clinical trial supplies are managed according to sponsor protocols. As a small molecule oral capsule, standard pharmaceutical storage conditions (room temperature, protected from moisture and light) are expected.
Community Dosing Protocols
Compare these clinical doses with what community members report using.
0View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Investigational Drug Disclaimer#
Bioglutide (NA-931) is an investigational drug that is not FDA-approved for any indication. All dosing information presented here is derived from clinical trial protocols and published results. Bioglutide is not available for prescription or purchase outside of clinical trials. The information below is provided for educational and research reference purposes only.
Clinical Trial Dosing#
Phase 1: Multiple Ascending Dose Study#
The Phase 1 study (NCT06615700) evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of NA-931 in a randomized, double-blind, placebo-controlled design.
Study population: 74 otherwise healthy adults who were overweight (BMI 27 or greater) or obese (BMI 30 or greater), with or without type 2 diabetes.
Design: Multiple ascending dose escalation over 28 days, with follow-up assessment at Day 35 (7 days after last dose).
Dose range: Ascending doses up to 150 mg daily (specific intermediate dose levels not publicly disclosed).
Key dosing findings:
- Doses of 60 mg and above demonstrated sustained placebo-adjusted weight loss
- Dose-dependent weight reduction up to 6.4% at Day 28
- Placebo-adjusted weight loss up to 5.3% maintained or improved at Day 35
- Up to 63% of treated subjects achieved 5% or more weight loss (versus 0% placebo)
- Pharmacokinetic data confirmed consistent blood levels supporting once-daily dosing
Phase 2: 13-Week Efficacy and Safety Study#
The Phase 2 study (NCT06564753) was a 13-week randomized, double-blind, placebo-controlled, parallel-arm, multiple ascending dose study.
Study population: 125 adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with at least one weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).
Dose tested: Up to 150 mg once daily oral capsule. The 150 mg daily dose achieved maximum efficacy.
Key dosing outcomes:
| Endpoint | NA-931 (150 mg daily) | Placebo |
|---|---|---|
| Mean weight loss at 13 weeks | 13.8% | ~1.4% |
| Placebo-adjusted weight loss | 12.4% | -- |
| Subjects achieving 12% or more weight loss | 72% | 2% |
| Muscle loss | None observed | -- |
Phase 2: Combination with Tirzepatide#
The combination study (NCT06732245) is evaluating NA-931 in combination with tirzepatide.
Study population: 224 adults with obesity (BMI 30 or greater) or overweight (BMI 27 or greater) with comorbidities, aged 19-80 years.
Design: NA-931 150 mg once daily oral capsule combined with tirzepatide subcutaneous injection. The study is designed to evaluate whether the combination produces synergistic effects on weight loss while reducing GI adverse events and preserving or increasing muscle mass.
Rationale: Preclinical studies showed that combining tirzepatide with NA-931 resulted in synergistic effects on weight loss, blood glucose control, and lipid metabolism. The combination may allow reduced tirzepatide doses, lowering GI side effects while maintaining efficacy.
Oral Administration#
Dosing Simplicity#
One of the notable features of Bioglutide is the simplicity of its oral administration:
- No fasting required: Unlike oral semaglutide (Rybelsus), which must be taken on an empty stomach with no more than 4 oz of water and a 30-minute wait before eating, Bioglutide can be taken without regard to food timing
- No absorption enhancer: Rybelsus requires SNAC to achieve approximately 0.4-1% oral bioavailability; Bioglutide achieves absorption through its inherent molecular properties
- No water restrictions: No specific water volume requirements for administration
- Flexible timing: Clinical data showed consistent blood levels whether taken fasting or with a high-fat meal, suggesting flexibility in timing of administration
Administration Instructions (from clinical trials)#
- Take one capsule once daily by mouth
- No specific timing relative to meals is required
- Swallow capsule whole
- Take at approximately the same time each day for consistency
Dose Comparison Context#
To contextualize Bioglutide's clinical dosing relative to other anti-obesity agents:
| Agent | Route | Dose | Frequency | Weight Loss | Duration |
|---|---|---|---|---|---|
| Bioglutide (NA-931) | Oral capsule | 150 mg | Once daily | 13.8% (Phase 2) | 13 weeks |
| Semaglutide (Wegovy) | SC injection | 2.4 mg | Once weekly | 14.9% (STEP 1) | 68 weeks |
| Tirzepatide (Zepbound) | SC injection | 15 mg | Once weekly | 22.5% (SURMOUNT-1) | 72 weeks |
| Oral semaglutide (Rybelsus) | Oral tablet | 14 mg | Once daily | ~5% (T2D; not approved for obesity) | 26 weeks |
| Orforglipron | Oral tablet | 36-72 mg | Once daily | ~14.7% (Phase 2) | 36 weeks |
Bioglutide's 13.8% weight loss at 13 weeks is notable given the short trial duration. Longer-duration Phase 3 trials will be needed to determine the full weight loss trajectory with sustained treatment.
Missed Dose Guidance#
No formal missed dose guidance has been published for Bioglutide. Based on the estimated 16-24 hour half-life and once-daily dosing regimen, general principles for daily medications would apply: take the missed dose as soon as remembered on the same day, or skip the missed dose if close to the next scheduled dose. Do not double doses.
Storage#
Specific storage conditions for Bioglutide have not been publicly detailed. As a small-molecule oral capsule, standard pharmaceutical storage conditions are expected (room temperature, protected from moisture and light). Clinical trial supplies are stored and dispensed according to the sponsor's protocol.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Bioglutide (NA-931)
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.